Abeona Therapeutics Inc
ABEO6.420USD
-0.070-1.08%
收盤 08/04, 16:00（美東）報價延遲15分鐘
314.28M總市值
虧損本益比TTM
關於 Abeona Therapeutics Inc 公司
Abeona Therapeutics Inc. 是一家臨牀階段的生物製藥公司。該公司致力於開發危及生命的疾病的細胞和基因療法。該公司的主要臨牀項目是 prademagene zamikeracel (pz-cel)，這是其研究性自體 COL7A1 基因校正表皮片，目前正在開發用於治療隱性營養不良性大皰性表皮鬆解症 (RDEB)。該公司完全集成的細胞和基因治療良好生產規範 (cGMP) 製造設施是其 III 期 VIITAL 試驗中使用的 pz-cel 的生產基地，能夠在 FDA 批准後支持 pz-cel 的商業化生產。該公司的開發組合還包括基於腺相關病毒 (AAV) 的基因療法，用於治療具有高度未滿足醫療需求的眼科疾病。該公司的新型下一代 AAV 衣殼正在接受評估，以改善各種毀滅性疾病的趨向性特徵。
公司簡介
公司代碼ABEO
公司名稱Abeona Therapeutics Inc
上市日期Sep 19, 1980
CEODr. Vishwas (Vish) Seshadri, Ph.D.
員工數量136
證券類型Ordinary Share
年結日Sep 19
公司地址6555 Carnegie Ave, 4th Floor
城市CLEVELAND
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編44103
電話16468134701
網址https://abeonatherapeutics.com/
公司代碼ABEO
上市日期Sep 19, 1980
CEODr. Vishwas (Vish) Seshadri, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.23M
-5.32%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
180.47K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
154.37K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
145.44K
-3.44%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
120.48K
-9.80%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
77.34K
-14.48%
Dr. Bernhardt G. Zeiher, M.D.
Dr. Bernhardt G. Zeiher, M.D.
Independent Director
Independent Director
47.15K
--
Dr. Eric Crombez, M.D.
Dr. Eric Crombez, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph Vazzano, CPA
Mr. Joseph Vazzano, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Faith L. Charles, J.D.
Ms. Faith L. Charles, J.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.23M
-5.32%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
180.47K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
154.37K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
145.44K
-3.44%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
120.48K
-9.80%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
77.34K
-14.48%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月12日 週六
更新時間: 7月12日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Suvretta Capital Management, LLC
7.20%
Nantahala Capital Management, LLC
6.86%
Adage Capital Management, L.P.
5.26%
Western Standard, LLC
4.46%
The Vanguard Group, Inc.
3.95%
Other
72.27%
持股股東
持股股東
佔比
Suvretta Capital Management, LLC
7.20%
Nantahala Capital Management, LLC
6.86%
Adage Capital Management, L.P.
5.26%
Western Standard, LLC
4.46%
The Vanguard Group, Inc.
3.95%
Other
72.27%
股東類型
持股股東
佔比
Hedge Fund
39.27%
Investment Advisor
9.65%
Investment Advisor/Hedge Fund
6.04%
Individual Investor
5.83%
Venture Capital
4.82%
Research Firm
3.12%
Pension Fund
0.17%
Other
31.08%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
154
35.41M
69.26%
-4.09M
2025Q1
147
35.53M
69.67%
-3.94M
2024Q4
142
35.48M
81.61%
-1.29M
2024Q3
136
33.53M
77.24%
-4.39M
2024Q2
136
35.81M
86.04%
+12.73M
2024Q1
132
18.43M
63.48%
+1.42M
2023Q4
122
17.76M
63.56%
+2.13M
2023Q3
129
13.60M
55.05%
-1.35M
2023Q2
141
10.67M
49.73%
+4.50K
2023Q1
170
7.90M
44.30%
-1.15M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Suvretta Capital Management, LLC
3.69M
7.2%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
3.51M
6.86%
-19.36K
-0.55%
Mar 31, 2025
Adage Capital Management, L.P.
2.69M
5.26%
-1.21M
-31.03%
Mar 31, 2025
Western Standard, LLC
2.28M
4.46%
+196.78K
+9.44%
Mar 31, 2025
The Vanguard Group, Inc.
2.02M
3.95%
+54.16K
+2.75%
Mar 31, 2025
Vivo Capital, LLC
1.84M
3.6%
--
--
Mar 31, 2025
Rosalind Advisors, Inc.
1.81M
3.53%
+427.00
+0.02%
Mar 31, 2025
Laurion Capital Management LP
1.31M
2.55%
--
--
Mar 31, 2025
Armistice Capital LLC
1.30M
2.54%
+1.30M
--
Dec 31, 2023
Seshadri (Vishwas)
1.30M
2.55%
-51.56K
-3.80%
Jun 06, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Simplify Propel Opportunities ETF
4.69%
iShares Neuroscience and Healthcare ETF
0.63%
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
查看更多
Simplify Propel Opportunities ETF
佔比4.69%
iShares Neuroscience and Healthcare ETF
佔比0.63%
iShares Micro-Cap ETF
佔比0.06%
iShares Russell 2000 Growth ETF
佔比0.02%
Proshares Ultra Russell 2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
公告日期
類型
比率
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
